Literature DB >> 6370863

Class specificity of naturally acquired and vaccine-induced antibody to type III group B streptococcal capsular polysaccharide: determination with a radioimmunoprecipitin assay.

M S Edwards, P A Fuselier, M A Rench, D L Kasper, C J Baker.   

Abstract

A radioimmunoprecipitin test was developed to determine the immunoglobulin class distribution of naturally acquired and vaccine-induced antibody to the native capsular polysaccharide of type III group B streptococci (III-GBS). In sera from adults and pregnant women with naturally acquired antibody, the mean percentage of antigen bound by immunoglobulin G (IgG) was 74.9 and 78.6, respectively, whereas antigen bound by IgM comprised less than 10% of the total. In contrast, early-convalescent-phase sera (mean, 16.3 days) from neonates responding to III-GBS infection with an increase in specific antibody had significantly more IgM (mean, 36%; P less than 0.001, unpaired t test). However, in late convalescence, the immunoglobulin class distribution in sera from these neonates was similar to that of naturally immune adults. Four weeks after immunization with III-GBS polysaccharide vaccine, sera from adults with low (less than 2 micrograms/ml) preimmunization antibody levels in their sera and from those with moderate (mean, 5.5 micrograms/ml) preimmunization levels contained specific antibody predominantly of the IgG class. Although the percentage of IgG-specific antibody was greater in sera from naturally immune adults than in that from vaccinees with a presumed primary immune response, the major portion of antigen bound by sera at 4 weeks postimmunization (62.5%) was associated with IgG. These observations support the opinion that immunization of pregnant women with III-GBS capsular polysaccharide could be efficacious for the prevention of invasive neonatal III-GBS disease.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6370863      PMCID: PMC263510          DOI: 10.1128/iai.44.2.257-261.1984

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  21 in total

1.  Some variable controls for accurate heterologous anti-immunoglobulin (HAI) tests.

Authors:  P Minden; R S Farr; J Trembath
Journal:  Immunochemistry       Date:  1975-07

2.  Gamma G subgroups in human fetal, cord, and maternal sera.

Authors:  P H Schur; E Alpert; C Alper
Journal:  Clin Immunol Immunopathol       Date:  1973-11

3.  Influence of gestational age on serum levels of alpha-1 fetoprotein, IgG globulin, and albumin in newborn infants.

Authors:  M Hyvarinen; P Zeltzer; W Oh; E R Stiehm
Journal:  J Pediatr       Date:  1973-03       Impact factor: 4.406

4.  Immunogenicity of polysaccharides from type III, group B Streptococcus.

Authors:  C J Baker; M S Edwards; D L Kasper
Journal:  J Clin Invest       Date:  1978-04       Impact factor: 14.808

5.  On the composition of IgG anti-IgG immune complexes.

Authors:  J Steensgaard; A S Johansen; C Jacobsen
Journal:  Immunology       Date:  1979-12       Impact factor: 7.397

6.  Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection.

Authors:  C J Baker; D L Kasper
Journal:  N Engl J Med       Date:  1976-04-01       Impact factor: 91.245

7.  Human immunity to group B streptococci measured by indirect immunofluorescence: correlation with protection in chick embryos.

Authors:  L C Vogel; R R Kretschmer; K M Boyer; D M Padnos; C A Gadzala; S P Gotoff
Journal:  J Infect Dis       Date:  1979-11       Impact factor: 5.226

8.  Assessment of group B streptococcal opsonins in human and rabbit serum by neutrophil chemiluminescence.

Authors:  V G Hemming; R T Hall; P G Rhodes; A O Shigeoka; H R Hill
Journal:  J Clin Invest       Date:  1976-12       Impact factor: 14.808

9.  Quantitative determination of antibody to capsular polysaccharide in infection with type III strains of group B Streptococcus.

Authors:  C J Baker; D L Kasper; A Paredes; S Alpert; W M McCormack; D Goroff
Journal:  J Clin Invest       Date:  1977-05       Impact factor: 14.808

10.  Immunochemical characterization of the "native" type III polysaccharide of group B Streptococcus.

Authors:  C J Baker; D L Kasper; C E Davis
Journal:  J Exp Med       Date:  1976-02-01       Impact factor: 14.307

View more
  7 in total

1.  Deposition and degradation of C3 on type III group B streptococci.

Authors:  J R Campbell; C J Baker; M S Edwards
Journal:  Infect Immun       Date:  1991-06       Impact factor: 3.441

2.  Passive protection by human sera in mice against challenge with strains of group B streptococci.

Authors:  Y Ichiman; K Yoshida
Journal:  Med Microbiol Immunol       Date:  1986       Impact factor: 3.402

3.  Synthesis and immunological properties of conjugates composed of group B streptococcus type III capsular polysaccharide covalently bound to tetanus toxoid.

Authors:  T Lagergard; J Shiloach; J B Robbins; R Schneerson
Journal:  Infect Immun       Date:  1990-03       Impact factor: 3.441

4.  Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus.

Authors:  M R Wessels; L C Paoletti; D L Kasper; J L DiFabio; F Michon; K Holme; H J Jennings
Journal:  J Clin Invest       Date:  1990-11       Impact factor: 14.808

5.  Immunoglobulin G and M composition of naturally occurring antibody to type III group B streptococci.

Authors:  B F Anthony; N F Concepcion; C A Wass; D C Heiner
Journal:  Infect Immun       Date:  1984-10       Impact factor: 3.441

6.  Isotype composition of antibodies to streptococcus group B type III polysaccharide and to tetanus toxoid in maternal, cord blood sera and in breast milk.

Authors:  T Lagergård; K Thiringer; L Wassén; R Schneerson; B Trollfors
Journal:  Eur J Pediatr       Date:  1992-02       Impact factor: 3.183

7.  Neutrophil Fc receptor participation in phagocytosis of type III group B streptococci.

Authors:  F J Noya; C J Baker; M S Edwards
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.